Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $26.82 million. The enterprise value is $95.36 million.
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 28.84 million shares outstanding. The number of shares has increased by 16.94% in one year.
| Current Share Class | 28.84M |
| Shares Outstanding | 28.84M |
| Shares Change (YoY) | +16.94% |
| Shares Change (QoQ) | +8.00% |
| Owned by Insiders (%) | 12.30% |
| Owned by Institutions (%) | 13.38% |
| Float | 18.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15
| Current Ratio | 0.15 |
| Quick Ratio | 0.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.93% |
| Return on Invested Capital (ROIC) | -153.63% |
| Return on Capital Employed (ROCE) | -221.05% |
| Weighted Average Cost of Capital (WACC) | 7.02% |
| Revenue Per Employee | $215,854 |
| Profits Per Employee | -$745,301 |
| Employee Count | 123 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 6.71 |
Taxes
In the past 12 months, Celularity has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.32% in the last 52 weeks. The beta is 0.45, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -41.32% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 30.13 |
| Average Volume (20 Days) | 51,140 |
Short Selling Information
The latest short interest is 226,425, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 226,425 |
| Short Previous Month | 294,642 |
| Short % of Shares Out | 0.79% |
| Short % of Float | 1.21% |
| Short Ratio (days to cover) | 6.98 |
Income Statement
In the last 12 months, Celularity had revenue of $26.55 million and -$91.67 million in losses. Loss per share was -$3.59.
| Revenue | 26.55M |
| Gross Profit | 6.48M |
| Operating Income | -59.40M |
| Pretax Income | -91.71M |
| Net Income | -91.67M |
| EBITDA | -54.01M |
| EBIT | -59.40M |
| Loss Per Share | -$3.59 |
Full Income StatementBalance Sheet
The company has $6.18 million in cash and $74.71 million in debt, with a net cash position of -$68.54 million or -$2.38 per share.
| Cash & Cash Equivalents | 6.18M |
| Total Debt | 74.71M |
| Net Cash | -68.54M |
| Net Cash Per Share | -$2.38 |
| Equity (Book Value) | -37.76M |
| Book Value Per Share | -1.32 |
| Working Capital | -68.14M |
Full Balance SheetCash Flow
| Operating Cash Flow | -13.25M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.38M |
| Net Borrowing | 10.79M |
| Free Cash Flow | -13.25M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
| Gross Margin | 24.39% |
| Operating Margin | -223.72% |
| Pretax Margin | -345.44% |
| Profit Margin | n/a |
| EBITDA Margin | -203.44% |
| EBIT Margin | -223.72% |
| FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.94% |
| Shareholder Yield | -16.94% |
| Earnings Yield | -341.82% |
| FCF Yield | -49.42% |
Analyst Forecast
The average price target for Celularity is $6.00, which is 545.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 545.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
